Hormonal steroids act as tumor promoters by modulating oncogene expression by Sekeris, Constantine E.
J Cancer Res Clin Oncol (1991) 117:96 101 
0t 7152169100020I 
C~eer I~esearch 
and 
Clinical 9 
9 Springer-Verlag 199l 
Guest editorial* 
Hormonal Steroids Act as Tumour Promoters 
by Modulating Oncogene Expression * * 
Constantine E. Sekeris 
Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, 
48 Vassileos Constantinou Avenue, Athens 11635, Greece 
Received 8May 1990/Accepted 17September 1990 
Summary. Recent advances in the molecular action of 
steroid hormones and in the role of oncogenes in cell 
transformation are considered in defining, at the molecu- 
lar level, the involvement of steroid hormones in tumour 
formation. In the context of the generally accepted three- 
stage model of carcinogenesis, t is proposed that the hor- 
monal steroids act as tumour promoters by modulating 
oncogene xpression. It is postulated that the hormonal 
steroids act on cells in which the initiating carcinogen has 
either induced mutations in protooncogenes normally 
hormonally regulated or has induced changes in gene 
architecture, aligning protooncogenes to hormone-re- 
sponsive elements, thus placing these genes under non- 
physiological hormonal control. In contrast o the de- 
fined action of solitary carcinogens on the genetic mate- 
rial, tumour promoters appear to act by various molecu- 
lar pathways, one of which, as hypothesized for hor- 
monal steroids, could be a direct effect on oncogene x- 
pression. 
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Introduction 
Clinical studies uggested effects of steroid hormones on 
tumour growth first in the classical observations by Beat- 
son (1886), who showed abeneficial effect of ovariectomy 
on patients with inoperable breast cancer. Similar obser- 
vations were made much later by Huggins (Huggins and 
Hodges 1941; Huggins et al. 194l) regarding the positive 
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effects of castration or of diethylstilbestrol administra- 
tion on prostatic carcinoma. A period of intense ex- 
perimentation, both in animal models and in cells in cul- 
ture, followed the isolation, determination of structure 
and synthesis of natural and synthetic hormonal steroids. 
Lacassagne in the early thirties was able to induce mam- 
mary tumours in male mice by administering oestradiol. 
Prolonged administration of oestrogens induced mam- 
mary tumours also in rats (Dunning et al. 1947), the de- 
gree of susceptibility to induction being strain-depen- 
dent. Kaufmann et al. (1949) demonstrated the appear- 
ance of mammary tumours in female mice after applica- 
tion of natural and synthetic oestrogens, the interval be- 
tween application of oestrogen and appearance of tu- 
mour being shorter, the larger the dose. In males, tumour 
appearance was much lower; however, high doses of hor- 
mones led to feminization of the animals, which then, as 
regards time of appearance and number of mammary tu- 
mours, behaved as females. Polycyclic-aromatic-hydro- 
carbon-induced mammary tumours in rats were intro- 
duced as an in vivo model by Huggins (Huggins et al. 
1959, 1961): breast cancers appeared only in intact female 
animals but not in oophorectomized ones. Ovarian graft- 
ing, however, at the time of administration of the carci- 
nogen, restored the capacity of tumour formation. 
Various in vitro cell models have been introduced in 
studies relating the effects of hormones to cell trans- 
formation, the MCF-7 breast cancer cell line (Soule et al. 
1973) being one of the most extensively exploited. The 
growth of these cells is arrested by antioestrogens, which 
induce a mid G-1 block.This effect is reversed by oes- 
trogens, and growth is restored. No growth of trans- 
planted MCF-7 cells in ovariectomized nude mice is ob- 
served, the cells remaining viable. However, the adminis- 
tration of oestrogens restores the capacity for growth and 
tumour formation in these animals. 
In all these studies the nature of steroid involvement 
in the process of tumour formation was the focus of inter- 
est. In contrast to the initially prevailing view of steroids 
as solitary carcinogens, Butenandt (1950) and Kaufmann 
et al. (1949) characterized oestrogens as ,,bedingt krebs- 
aus16sende Faktoren", i.e. "conditional carcinogens", 
mainly substances that are not carcinogenic per se but in- 
duce the increased appearance of tumours in organisms 
showing an increased susceptibility for tumour forma- 
tion. 
Stages in carcinogenesis and involvement 
of steroid hormones 
In recent years, particularly in the example of skin carci- 
nogenesis, a model of tumour formation has been clearly 
formulated comprising three operationally defined stages 
(Hecker 1987). The first stage, initiation, is induced by 
the solitary carcinogen, which can be a chemical or a 
physical agent, but also a virus. It damages the genetic 
material, in the form of a point mutation or a deletion or 
by even more drastic hanges, such as gene rearrangement, 
insertion or chromosomal translocation. The change is 
sudden and persists for long time. The initiated cell re- 
mains in a condition of latency, unless subjected to the 
action of promotors, whose main, but not sole, effect is 
to stimulate cell proliferation. In the case of skin carcino- 
genesis, the well-characterized promotor, 12-O-tetrade- 
canoylphorbol 13-acetate, binds specifically to cell recep- 
tors. By way of phosphokinase C stimulation and the in- 
ositol/phopholipid/diacylglycerol system, it acts as a tis- 
sue-specific mitogen, but does not damage DNA (Hecker 
1987). During this stage benign turnouts appear, and oc- 
casionally also a few malignant ones. Exposure of the be- 
nign tumours to another single dose of the solitary carci- 
nogen increases significantly the proportion of the malig- 
nant tumours (progression phase) and the tumour cells 
acquire more and more aberrant characteristics. Thus, 
the solitary carcinogen acts as both an initiator as well as 
a progressor. 
Considering a general multistage concept of carcino- 
genesis and the described effects of steroids on tumour 
formation, the question arises as to the stage of tumori- 
genesis that is affected by the hormonal steroids. There are 
no indications of a chemical modification of DNA by the 
steroids, i.e. they are not mutagenic. This excludes them 
from the category of initiators of carcinogenesis. Rather 
the fact that in the various animal models they must act 
for a long period of time with repeated exposures, in 
order to induce carcinogenesis, and the demonstration 
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that both androgens and oestrogens are powerful mi- 
togens promoting cell division in their target organs, e.g. 
prostate, breast and cervix, place them in the category of 
promotors, or ,,bedingt krebsauslSsende Faktoren", ac- 
cording to Butenandt. However, in contrast to the 
progressively increasing knowledge of the molecular 
mechanism of action of the classical skin-tumour promo- 
tors, such as 12-O-tetradecancylphorbol 13-acetate 
(Hecker 1987), our concepts regarding the molecular ac- 
tion of steroid hormones as promotors of carcinogenesis 
are still rudimentary. 
Taking into account he major advances in the molec- 
ular mechanisms of hormone action and the remarkable 
progress in our understanding of the role of oncogenes in
cell transformation, the hypothesis that the promoting ef- 
fects of steroids in tumorigenesis are mediated through 
modulation of oncogene xpression will be supported. 
Molecular action of steroid hormones 
It is now well established that steroid hormones exert 
their physiological functions by way of gene activation 
and induction of protein synthesis as postulated by Karl- 
son (1961). The hormone specifically and with high affin- 
ity binds to the respective receptor protein, which then 
acts as a trans-acting transcription modulator (Evans 
1988; Green and Chambon 1988; Beato et al. 1989) by 
binding to specific DNA sequences, the hormone-re- 
sponsive lements (HREs). Cloning of the various steroid 
receptor genes has led to the demonstration of common 
structural features in these molecules, important for their 
intreaction with the steroid ligand, with the DNA, as well 
as with other regulatory macromolecules (Fig. 1). 
The DNA-binding domain of the receptors is highly 
conserved, consisting of 66-68 amino acids rich in cys- 
teines and basic amino acids, showing similarity with the 
"zinc finger" motif  characteristic of TFII IA, the tran- 
scription factor of the 5S-RNA gene and of other DNA- 
binding proteins. 
The HREs represent palindromic, 15-base-pair struc- 
tures, showing a dyad symmetry (Fig. 2) suggesting that 
the receptor binds to these sequences as a dimer. The re- 
ceptors for glucocorticoids, mineralocorticoids, proges- 
terone and androgen recognize a common HRE, the oes- 
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Fig. 1. Schematic representation f a steroid receptor. All steroid receptors examined exhibit (a) a variable N-terminal region (A/B) believed 
to have a modulatory effect on trans-activation (b)a central domain (C), well conserved and rich in cysteines responsible for DNA binding, 
and (c) a C-terminal domain (E), responsible for binding of the hormonal steroid. Regions involved in additional functions, uch as nuclear 
translocation, transactivation a d binding of the 90-kDa heat-shock protein, are also indicated (from Beato et al. 1989) 
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Fig. 2. Consensus-responsive elements (RE) for nuclear eceptors. 
GRE, glucocorticoid RE; PRE, progesterone RE; ARE, androgen 
RE; MRE, mineralocorticoid RE; ERE, oestrogen RE; EcRE, ec- 
dysone RE; TRE, thyroid hormone RE; RRE, retinoic acid RE. 
(From Beato et al. 1989) 
trogens adifferent one (Fig. 2). The HREs are distributed 
at various positions of the hormone-regulated genes, near 
the promoter, at various distances in the 5'-upstream re- 
gion or within the gene itself. 
Some genes contain more than one HRE, which in re- 
ceptor-binding experiments and transfection studies with 
chimaeric genes make variable contributions as hor- 
mone-inducible nhancer elements and act synergisti- 
cally. In some cases, even sequences that are half-palin- 
dromic but in multiple copies can confer hormone indu- 
cibility to the respective gene. A series of other regulatory 
sequences interacting with general and tissue-specific fac- 
tors serve to modulate the hormonal effects. 
Oncogenes and human cancer 
Protooncogenes affect cellular regulation, growth and 
developmental processes through their respective n- 
coded proteins, which belong to various categories of 
regulatory macromolecules, uch as growth factors, 
growth-factor receptors, GTP-binding proteins and nu- 
clear proteins involved in transcription regulation (Wein- 
berg 1985). The realization that the expression of a mu- 
tated protooncogene product or the overexpression or
untimely expression of an otherwise normal protoonco- 
Table 2. Amplification of oncogenes in various human and animal 
tumours  
Oncogene Tumour 
c-myc 
N-myc 
c-Ki-ras-2 
N-ras 
c-er b B 2 
c-abl 
c-myb 
int-2 
Breast carcinoma 
Promyelocytic leukemia, colon carcinoma, 
small-cell ung carcinoma 
Neuroblastoma, retinoblastoma, small-cell lung 
carcinoma 
Lung carcinoma, bladder carcinoma 
Mammary carcinoma 
Breast carcinoma, ovarian carcinoma 
Chronic granulocytic leukemia 
Colon carcinoma 
Breast carcinoma 
gene is a major causal factor in cell transformation was 
a major breakthrough in our concept of carcinogenesis. 
This resulted in a series of studies dealing with the role of 
increased expression of normal or of mutated protoonco- 
genes in the pathogenesis of human tumours. An in- 
creased expression of protooncogenes has been noted in 
a series of human tumours (Table 1). In many cases, am- 
plification of several oncogenes has also been observed 
(Table 2). 
A possible causal relationship between oncogene x- 
pression and tumorigenesis in humans will be illustrated 
on the paradigm of the HER-2 gene. A detailed study of 
the expression of this protooncogene in human breast 
cancer has recently appeared (Slamon et al. 1989). The 
HER-2 (c-erbB2) is the human homologue of the c-neu 
gene, cloned from a rat neuroglioblastoma, coding for a 
transmembrane protein, with extra- and intracellular do- 
mains, and partially homologous to the tyrosine kinase 
family of growth-factor receptors. In 25%-30% of hu- 
man primary breast cancers this protooncogene is ampli- 
fied, the degreee of amplification being negatively corre- 
lated to disease-free and overall survival. It was also 
shown that amplification was accompanied with in- 
creased expression of the corresponding mRNA and pro- 
tein products. The expressed protein is identical to the 
one expressed in normal tissues, with the exception of a 
neutral substitution (isoleucine for valine) at position 655 
of the transmembrane domain. The HER-2 gene is am- 
plified and overexpressed also in human ovarian tu- 
mours, with a similar negative correlation between over- 
Table 1. Increased expression of oncogenes inhuman neoplasms 
Oncogene Cellular function Tumour 
N-ras 
H-ras-1 
K-ras-2 
neu (erbB2, HER-2) 
int-2 
abl 
c-myc 
mos 
sis 
GTP-binding protein 
GTP-binding protein 
GTP-binding protein 
Growth factor eceptor 
Growth-factor-like 
Membrane-associated Tyr kinase 
Nuclear transcription factor 
Cytoplasmic threonine kinase 
Platelet-derived growth factor 2 
Neuroblastoma 
Wilm's tumour 
Chronic lymphoblastic leukemia 
Mammary carcinoma 
Mammary carcinoma 
Chronic myelogenous leukemia, cute lymphoblastic leukemia, 
acute myelogenous leukemia 
Burkitt's lymphoma 
Acute myelogenous leukemia 
Chronic myelogenous leukemia 
Burkitt's lymphoma 
expression and disease - free interval. Amplification of 
the protooncogene proved to be a prognostic factor supe- 
rior to the oestrogen- and progesterone-receptor status of 
the tumours. A direct causal relationship between the in- 
creased expression of HER-2  and cell transformation has 
been shown by Hudziak et al. (1987), who transfected 
3T3 cells with HER-2,  which led to amplification of the 
unaltered gene in these cells, overexpression f the respec- 
tive protein, cellular transformation a d subsequent tu- 
mour formation upon grafting of the transformed cells to 
athymic mice. Muller et al. (1988) demonstrated in trans- 
genic mice that the activated c-neu gene linked to a mouse 
mammary turnouts virus (MMTV) promotor resulted in 
the appearance of mammary adenocarcinomas, leading 
the authors to the conclusion that the expression solely of 
the c-neu oncogene is sufficient o induce malignant 
transformation. Similar experiments were performed by 
Bouchard et al. (1989), who concluded that the ex- 
pression of the c-neu oncogene was necessary, but not 
sufficient, to induce malignant ransformation. Bou- 
chard et al. (1989) used constructs having the MMTV 
long terminal repeat immediately adjacent o the neu 
cDNA, whereas in the constructs of Muller et al. (1988) 
the MMTV long terminal repeat and the neu cDNA se- 
quences were separated by a 600-base-pair sequence, re- 
presenting the rat 30S sequences derived from the Harvey 
murine sarcoma virus genome. This could account for 
the observed ifferences between the results of the two 
groups. These differences notwithstanding, the presence 
of long terminal repeat sequences containing several 
HREs in the constructs used, and the expression of c-neu 
in th e mamma epithelium, a primary target tissue for hor- 
monal steroids, strongly suggests the importance of ste- 
roid hormones, in this specific case of sex steroids, in on- 
cogene xpression and oncogenesis ( ee below). 
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GGTCTGCCTAGGC-3' is present at position 2102- 
2114 of the gene. It is thus suggested that the effects of 
oestrogens on c-fos, and probably also on c-myc, ex- 
pression are mediated by direct interaction of the hor- 
mone-receptor complex with these sequences, which 
could represent oestrogen-responsive el ments instru- 
mental for c-fos activation. 
A search for the presence of various HREs in pro- 
tooncogenes, whose expression is increased invarious tu- 
mours, has indeed revealed such sequences and has initi- 
ated studies on the hormonal inducibility of the respec- 
tive genes. It is important to note that many retroviruses 
involved in tumour induction in animals - a classic ex- 
ample being the MMTV - but also human retrovirus and 
HIV-1, have HREs in their genome (Miksicek et al. 
1986). The effects of various steroid hormones on 
MMTV are well documented. The experiments ofMuller 
et al. (1988) and Bouchard et al. (1989) have already been 
mentioned above. Markham et al. (1986) have shown 
that the ability of HIV-1 to infect human peripheral 
blood monocytes productively was improved by hydro- 
cortisone. That this effect is mediated by the glucocor- 
ticoid-responsive element present in the virus genome is 
suggested in transfection assays (Spandidos et al. 1990). 
The human papillomavirus type 16 in combination 
with an activated H-ras gene transforms primary cells 
only in the presence of the glucocorticoid hormone 
dexamethasone. It has been found that the HPV-16 
genome carries a glucocorticoid-responsive el ment 
sequence (Pater et al. 1988). In this respect the paper by 
Stavenhagen and Robins (1988) should be mentioned 
showing that the mouse sex-limited protein gene has been 
rendered androgen-dependent through endogenous virus 
insertion, having an HRE in its 5' long terminal repeat 
2 kb upstream of the gene. 
Hormonal control of protooncogene expression 
A wealth of information has been recently amassed on 
the direct effects of steroid hormones on protooncogene 
expression. Interesting in this respect are the effects of 
oestrogens on the expression of c-fos (Loose-Mitchell et 
al. 1988; Weisz and Bresciani 1988) and c-myc (Weisz and 
Bresciani 1988) in rat uterus. Administration of oestra- 
diol to immature rats causes within 30 min an increase of 
c-fos mRNA, reaching amaximum at 3 h (Loose-Mitch- 
ell et al. 1988). This effect is abolished by actinomycin D.
Other steroid hormones, such as dexamethasone, dihy- 
drotestosterone and progesterone, had no such effect. 
Weisz and Bresciani (1988) followed the effects of oes- 
trogens on the expression of 20 protooncogenes, c-fos 
and c-rnyc responded very rapidly, within 30 min and 
90 min, respectively, to the hormone, whereas the other 
oncogenes did not respond to the hormonal stimulation. 
Loose-Mitchell et al. (1988) demonstrated the presence of 
a 12-base-pair sequence having a sequence 5'- 
GGTCTAGGAGACC-3' at position -219-207 with re- 
spect o the start site of transcription, similar to the palin- 
dromic oestrogen-responsive element in the Xenopus vi- 
tellogenin gene. Another similar sequence 5'- 
Possible mechanisms of steroid hormone involvement 
in cell transformation 
Steroid hormones represent one of the most important 
categories of regulatory molecules, controlling cellular 
growth, proliferation, and differentiation, as well as met- 
abolic processes. Most of these effects are mediated by 
regulation of key genes, such as the protooncogenes, in a 
precisely defined temporal and tissue-specific pattern. 
Expression of mutated or of normal genes at an inappro- 
priate time period or location could have grave con- 
sequenes for various cellular functions. If the affected 
genes belong to the protooncogene family, the link to cel- 
lular transformation is obvious. As mentioned above, 
some protooncogenes seem to be under the direct control 
of steroid hormones. Mutations in these genes as a con- 
sequence of action of a carcinogen would lead to a hor- 
mone-dependent synthesis of mutated proteins, and their 
involvement in the cell transformation process. 
A similar effect on cell transformation would result if 
the carcinogen were to induce an alignment of a protoon- 
cogene, normally not subjected to hormonal control, to 
hormone-responsive el ments, rendering it steroid-hor- 
mone-dependent. 
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Gene rearrangement and chromosomal translocation 
are such possibilities. Chorazy (1985) has discussed the 
role of movable genetic elements in this context. In a 
study on chromosomal rearrangement i  leukemias and 
various olid turnours, de Braekeller (1988) demonstrated 
preferential breakage and deletions in bands known to 
contain protooncogenes, growth factor receptor and dif- 
ferentiation genes. 
Insertional mutagenesis, i.e. integration of viral se- 
quences, containing HREs in their regulatory regions, 
near protooncogenes is one potential basic mechanism of 
conferring hormone responsiveness to protooncogenes. 
The role of MMTV in breast umour formation (Peters 
et al. 1983) and the effects of sex steroids on this process 
is one such classic example. Conforming with this notion 
are results, already referred to, of androgen dependence 
of the mouse sex-limited protein gene caused by endoge- 
nous virus insertion, possessing an HRE in its long termi- 
nal repeat (Stavenhagen and Robins 1988). As already 
mentioned, in many of the tumours showing increased 
expression of protooncogenes, a parallel amplification of 
the expressed gene is also observed. It is possible that 
some of the amplified genes could be positioned near 
HREs, rendering the genes responive to the hormonal 
stimulus. It should be mentioned that steroid hormones 
not only stimulate but also repress gene activity; there- 
fore, the possibility should also be considered that, with 
mechanisms similar in principle to those described above, 
oncosuppressor genes could be repressed, and therefore 
also the synthesis of tumour inhibitory substances, 
which are thought o be the products of these genes. 
Conc lus ions  
On the basis of the above considerations and taking into 
account he three-stage model of carcinogenesis, the role 
of steroid hormones in turnout formation can be re- 
garded as that of a conditional carcinogen or a promotor 
(Butenandt 1950), acting on cells already initiated by the 
action of the solitary carcinogen, i.e. on cells on which the 
carcinogen has damaged hormone-responsive protoon- 
cogenes or has provoked alignment ofprotooncogenes to 
hormone-responsive elements. In the specific ase of hor- 
monal steroids the promoting role of the hormone is visu- 
alized as a direct action of the hormone in the form of its 
complex with the receptor, on genes involved in cell pro- 
liferation and differentiation. Other turnour promoters 
act by other mechanisms. In the case of the tumour pro- 
motor 12-O-tetradecanoylphorbol 13-acetate, well stud- 
ied both at the level of experimental pathology and of 
biochemistry (Hecker 1978, 1987), the action on cell pro- 
liferation is exerted at the level of the membrane, by way 
of activation of the inositol phospholipid iacylphos- 
phate/phosphokinase C pathway. Other prornotors 
could exert their cell-proliferative effects by activating 
other key sites in the chain of events leading to DNA rep- 
lication. The possibility that hormone inducibility of a 
gene could be influenced by effects on regulatory ele- 
ments other than the HREs or on changes in the structure 
and function of the steroid-receptor molecule itself has 
not been discussed, but certainly represents a field of fu- 
ture research endeavours. 
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